Dennis A. Clements
  • Dennis A. Clements

  • Professor of Pediatrics and Chief, Division of Primary Care Pediatrics and Research Professor of Global Health and Professor of Community and Family Medicine and School of Nursing and Professor of Medicine
  • Center for Latin American Caribbean Studies
  • Room 116, Trent Hall, 310 Trent Drive, Durham, NC 27708
  • Campus Box 90519
  • Pager: (919) 970-5774
  • Homepage
  • Overview

    1) Vaccine Research - safety, tolerability, and immunogenicity, effectiveness.
    2) Infectious Disease Epidemiology - otitis media, day care, outbreaks
    3) Cost effectiveness of vaccination strategies.
    4)Latino health issues, medical Spanish education, cultural sensitivity.
    5) Health Care Delivery Systems - contracting, business plans, access to care, management, finances
    6) Health Manpower needs in the third world
    7) Education - medical school, graduate school and undergraduate
  • Specialties

    • Pediatrics
  • Education

      • Ph.D.,
      • University of North Carolina at Chapel Hill,
      • 1990
      • M.P.H.,
      • University of North Carolina at Chapel Hill,
      • 1988
      • M.D.,
      • University of Rochester,
      • 1973
  • Recent Publications

      • MD Gunderson, D Clements and SE Benjamin Neelon.
      • "Nutritional quality of foods marketed to children in Honduras.."
      • Appetite
      • 73
      • (2014)
      • :
      • 1-6.
      • [web]
      Publication Description

      Evidence suggests that exposure to advertising of unhealthy foods may contribute to increased rates of obesity in children. This study examined the extent to which television stations marketed unhealthy foods to children during after-school programming aired over one week in La Ceiba, Honduras. Content analysis was performed on four television stations, including one broadcast station and three cable networks. Eighty hours of programming were recorded and analyzed. Advertised products were categorized as food or non-food items, with food items further classified as healthy or unhealthy. Advertisements were coded as those aimed at children, adults, or both, and chi-square tests were used to compare the proportion of unhealthy advertisements by target audience. A total of 2271 advertisements aired during the observation period, with 1120 marketing products (49.3%). Of those, 397 (35.4%) promoted foods-30.2% were for healthy foods and 69.8% for unhealthy foods. The unhealthy foods were all advertised on cable networks and not the broadcast station. Children appeared to be targeted more than adults in advertisements for unhealthy foods (92.1%, p

      • EB Walter and DA Clements.
      • "Pneumococcal conjugate vaccine: are 3 doses equal to 4 doses?."
      • Pediatrics
      • 132
      • .2
      • (2013)
      • :
      • e498-e499.
      • [web]
      • EB Walter, MA Snyder, DA Clements, SL Katz.
      • "Large injection site reactions after a second dose of varicella vaccine.."
      • Pediatr Infect Dis J
      • 27
      • .8
      • (2008)
      • :
      • 757-759.
      • [web]
      Publication Description

      A second dose of varicella vaccine is routinely recommended. We report 2 cases of large local reactions after receipt of a second dose of varicella vaccine administered in the thigh. The reactions resolved with symptomatic therapy. Clinicians should continue to administer the second dose of varicella vaccine, but should use the preferred site in the arm.

      • CW Woods, AM Bressler, JJ LiPuma, BD Alexander, DA Clements, DJ Weber, CM Moore, LB Reller, KS Kaye.
      • "Virulence associated with outbreak-related strains of Burkholderia cepacia complex among a cohort of patients with bacteremia.."
      • Clin Infect Dis
      • 38
      • .9
      • (2004)
      • :
      • 1243-1250.
      • [web]
      Publication Description

      The Burkholderia cepacia complex includes 9 genomovars. The relative virulence of each is unknown. Host and pathogen features associated with mortality were evaluated among patients with B. cepacia complex bacteremia. Cases were ascertained through review of blood culture results for the period of May 1996 through May 2002. Isolates were identified to species level with 16S rDNA and recA-based species-specific polymerase chain reaction analyses and recA restriction fragment-length polymorphism. Strain typing was performed with pulsed-field gel electrophoresis. Fifty-three patients with B. cepacia complex bacteremia were identified; only 9 (17%) had cystic fibrosis. Twenty-five patients (47%) died within 14 days of bacteremia. After controlling for comorbid conditions and therapeutic interventions, 2 outbreak-related strains of Burkholderia cenocepacia (genomovar III) were associated with 14-day mortality (odds ratio, 5.5; 95% confidence interval, 1.20-25.02). B. cenocepacia is an emerging nosocomial pathogen. Certain strains are associated with an enhanced capacity for interpatient spread and poor outcome.

      • PY Lee, DB Matchar, DA Clements, J Huber, JD Hamilton, ED Peterson.
      • "Economic analysis of influenza vaccination and antiviral treatment for healthy working adults.."
      • Ann Intern Med
      • 137
      • .4
      • (2002)
      • :
      • 225-231.
      • [web]
      Publication Description

      BACKGROUND: Physicians have several treatment options for influenza, including vaccination and various antiviral therapies. However, the optimal influenza prevention and treatment strategy is unknown. OBJECTIVE: To compare the relative health values of contemporary treatment strategies for influenza in a healthy sample of working adults. DESIGN: Cost-benefit analysis using a decision model. DATA SOURCES: Previously published data. TARGET POPULATION: Healthy employed adults 18 to 50 years of age. TIME HORIZON: A complete influenza season. PERSPECTIVE: Societal. INTERVENTIONS: Eight treatment options (yes or no) based on the possible combinations of vaccination and antiviral therapy (rimantadine, oseltamivir, or zanamivir or no treatment) should infection develop. OUTCOME MEASURES: Cost in U.S. dollars, including the value of symptom relief and medication side effects, which was assigned a monetary value through a conjoint analysis that used a "willingness-to-pay" approach. RESULTS: In the base-case analysis, all strategies for influenza vaccination had a higher net benefit than the nonvaccination strategies. Vaccination and use of rimantadine, the most cost-beneficial strategy, was $30.97 more cost-beneficial than nonvaccination and no use of antiviral medication. The health benefits of most antiviral treatments equaled or exceeded their costs for most scenarios. The choice of the most cost-beneficial antiviral strategy was sensitive to the prevalence of influenza B and to the comparative workdays gained by each antiviral therapy. CONCLUSIONS: Vaccination is cost-beneficial in most influenza seasons in healthy working adults. Although the benefits of antiviral therapy for persons with influenza infection appear to justify its cost, head-to-head trials of the various antiviral therapies are needed to determine the optimal treatment strategy.

  • View All Publications
  • Teaching

    • INTERDIS 155B.16
      • TBA
      • 12:00 AM-11:59 PM
    • INTERDIS 156B.16
      • TBA
      • 12:00 AM-11:59 PM
    • GHS 301B.16
      • TBA
      • 12:00 AM-11:59 PM
    • GHS 301B.16-S
      • TBA
      • 12:00 AM-11:59 PM
    • GLHLTH 501.01
      • Trent 124
      • Th 01:25 PM-03:55 PM
  • black